Day: August 25, 2023

H&H Group achieves robust double-digit top-line growth in the first half of 2023, setting the Group up for a positive growth outlook for the full year

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

LONDON, Aug. 25, 2023 (GLOBE NEWSWIRE) — Leading global family nutrition company, Health and Happiness (H&H) International Holdings Limited (HKSE: 1112), has announced its interim results for the six months ended 30 June 2023, delivering double-digit top-line growth to place the Group on a strong trajectory for the remainder of the year.The Group achieved revenue growth of 17.2% on a reported and like-for-like (“LFL”) basis and positive EBITDA margin across each of its three strategic business pillars, as well as healthy profitability and cash flow High-margin and fast-growing nutritional supplements across three business pillars have become the largest revenue contributor, making up 60.1% of the Group’s total revenue Adult Nutrition and Care (ANC) segment has now become the Group’s largest growth contributor delivering...

Semaglutide 2.4 mg shows large reductions in heart failure-related symptoms and physical limitations in people with heart failure with preserved ejection fraction and obesity

Written by Customer Service on August 25, 2023. Posted in Public Companies.

Amsterdam, Netherlands, 25 August 2023 – Novo Nordisk today announced results from the phase 3 STEP HFpEF trial showing that compared with placebo, once-weekly semaglutide 2.4 mg led to large reductions in heart failure-related symptoms, physical limitations and improvements in exercise function, and resulted in greater weight loss in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.1 HFpEF comprises roughly half of all heart failure cases2 and is associated with a high burden of symptoms and physical limitations affecting daily life,3 including fatigue, shortness of breath, reduced ability to exercise, and swelling of extremities. The majority (80%) of people with HFpEF also live with overweight or obesity, which is linked to a higher burden of symptoms, worse physical function and lower quality of life.4-6 The...

Industrial Protective Clothing Market to Worth USD 32.72 Billion by 2030 | Skyquest Technology

Written by Customer Service on August 25, 2023. Posted in Mergers And Acquisitions.

Industrial protective clothing market segmentation is based on product, application, material type and end user. Based on product, the market is segmented into durable and disposable. Based on application, the market is segmented into thermal, mechanical, chemical, biological/radiation, and others. Based on material type, the market is segmented into Aramid & blends, polyolefin & blends, polybenzimidaloe (PBI), cotton fibers, laminated polyesters, and others. Based on end user, the market is segmented into oil & gas, construction & manufacturing, pharmaceuticals/medical, military & defense, firefighting, and others- Industry forecast 2023-2030 Westford, USA, Aug. 25, 2023 (GLOBE NEWSWIRE) — According to SkyQuest, the industrial protective clothing market is poised for growth due to the escalating demand...

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – June 30, 2023

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients (1824 out of the planned 2158), and with the current rate of approximately 75 patients per month, we anticipate completing the recruitment by the end of the year. In June, the Data Monitoring Committee (DMC) concluded its scheduled safety analysis of data from the first 1400 recruited patients. The DMC’s conclusion is that the study can proceed as planned without any reservations. The DMC also conducted a futility analysis to determine if the trial has the potential to achieve statistically significant results, and once again, the conclusion was that the clinical work can continue as scheduled. No further DMC reviews are planned, and we are now approaching...

Quarterly Results for the 3 months ending 30 June 2023

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

Shares issued to Bacchus Capital LONDON and VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) — Mkango Resources Ltd (AIM / TSX-V:MKA) (the “Company” or “Mkango”), is pleased to announce that it has released its Financial Statements and Management Discussion and Analysis for the 6-month period ended 30 June 2023. The reports are available under the Company’s profile on the SEDARplus website (https://www.sedarplus.com/landingpage/) and on the Company’s website (https://mkango.ca/investors/financials/). Furthermore, Mkango has agreed to issue 280,678 shares (the “Shares”) to Bacchus Capital Advisors Limited (“Bacchus Capital”), an arm’s length party to Mkango, in connection with the strategic and financial advisory services provided by Bacchus Capital to the Company for the period from 1 April 2023 to 30 June...

Interim Report – January-June 2023

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

STOCKHOLM – 25 August 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report – January–June 2023. The full report is available on the Company’s website. “Our portfolio companies continue to deliver significant progress and we are following the developments of the studies that have been initiated this year, as well as the processing of the clinical results that have already been generated with great interest. Research and development activities are the basis for the companies’ long-term value creation and every advancement in the individual projects increases the possibility of ultimately being able to offer patient groups with major medical needs completely new types of treatments.”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the second quarterThe...

Hofseth Biocare ASA: SECOND QUARTER 2023 FINANCIAL REPORT

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and strong increase in margins. Sales revenues ended at NOK 52.9m vs NOK 25.8m last year. The underlying growth is coming from both the ingredients business and finished products channels. In June, HBC announced the sale of patents to the newly established associated company, HBC Immunology Llc. (HBCI) in USA. The net proceeds from this sale of assets amounts to NOK 23.5m, resulting in total operating revenues in Q2 of NOK 76.4m. HBCI will focus on the discovery and development of peptides that normalize tumor micro-environments for co-treatment of prostate cancer, resulting in the improved performance of immunotherapies and chemotherapies. HBC holds 75 % shareholding in HBCI. Adjusted for the sale of assets to HBCI, operating revenues in the...

HONKARAKENNE OYJ HALF-YEAR REPORT 1 JANUARY TO 30 JUNE 2023

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

HONKARAKENNE OYJ HALF-YEAR REPORT 25 AUGUST 2023 AT 9:00 HONKARAKENNE OYJ HALF-YEAR REPORT 1 JANUARY TO 30 JUNE 2023 NET SALES AND OPERATING PROFIT DECLINED – ORDER BOOK AT PRE-PANDEMIC LEVEL Net sales for the first half of 2023 declined by 37% to EUR 23.0 million (H1 2022: 36.7). Operating profit excluding items affecting comparability deteriorated by EUR -1.9 million to EUR 0.3 million (EUR 2.2 million). The result for the review period was negative. At the end of the review period, the order book stood at EUR 28.0 million. January-June 2023Honkarakenne Group’s net sales in January–June amounted to EUR 23.0 million (H1 2022: 36.7). Net sales declined by 24% from the corresponding period of the previous year. Operating profit was slightly negative and amounted to EUR -0.0 million (2.2). Adjusted operating...

DIGITALIST GROUP’S HALF-YEAR REVIEW, 1 JANUARY–30 JUNE 2023

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

DIGITALIST GROUP PLC HALF-YEAR REVIEW 25 AUGUST 2023, 9:00 AM DIGITALIST GROUP’S HALF-YEAR REVIEW, 1 JANUARY–30 JUNE 2023 SUMMARY April–June 2023 (comparable figures for 2022 in parentheses):Turnover: EUR 4.3 million (EUR 5.3 million), decrease: 17.9%. EBITDA: EUR -0.6 million (EUR -0.9 million), -13.7% of turnover (-17.0%). EBIT: EUR -0.8 million (EUR -1.3 million), -18.1% of turnover (-25.4%). Net income: EUR -1.2 million (EUR -2.1 million), -27.9% of turnover (-39.6%). Earnings per share (diluted and undiluted): EUR -0.00 (EUR -0.00).January–June 2023 (comparable figures for 2022 in parentheses):Turnover: EUR 8.9 million (EUR 10.4 million), decrease: 14.3%. EBITDA: EUR -0.9 million (EUR -1.4 million), -10.3% of turnover (-13.4%). EBIT: EUR -1.3 million (EUR -2.3 million), -15.0% of turnover (-22.0%). Net income:...

MT Højgaard Holding A/S: High growth in the Danish core business in H1

Written by Customer Service on August 25, 2023. Posted in Earnings Releases And Operating Results.

RESULTS FOR THE FIRST HALF OF THE YEAR The profitability of the Danish core business improved in the first half of the year, but the improvement was eclipsed by a considerable operating loss recorded by MT Højgaard International whose activities are being scaled down in a controlled process.Group revenue increased by 24% to DKK 4.9 billion, driven by double-digit growth in the Danish business units. Group operating profit before special items decreased by 40% to DKK 64 million. The Danish core business consisting of MT Højgaard Danmark, Enemærke & Petersen and MT Højgaard Property Development increased its operating profit by 39% to DKK 147 million, and the operating margin rose from 2.9% to 3.2%. MT Højgaard International’s operating profit before special items deteriorated, and the business unit recorded a loss of DKK 83...

Day: August 25, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice